Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...
moneycontrol.com3h
Dr Reddy's sets sight on 5th spot in Indian pharma market within 5 years
On the way, it acquired Sanofi India's vaccine portfolio, which has helped it deliver double-digit domestic growth in the ...
medtechintelligence2d
Sanofi adopts platform to handle multiple National Regulatory Authority submission
With numerous planned submissions underway for 2024, the new platform is setting a new standard for managing simultaneous ...
GlobalData on MSN2d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
FiercePharma3d
While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic Esophagitis
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
Wall Street expects Trump presidency will unlock deal-making
Also last year, the FTC blocked Sanofi’s proposed acquisition of a drug in development for Pompe disease, a genetic condition ...
Drone program coming to Pocono Township Police Department
The Pocono Township Police Department (PTPD) will be implementing a drone program. On Oct. 7, the Pocono Township Board of ...
The Accumulus Platform Powers Sanofi’s Submissions to Multiple Regulators Around the World
Sanofi’s adoption of the Accumulus platform marks another move towards fit-for-purpose technology that ensures secure, real-time global regulatory connectivity. Many of the NRAs involved in the Sanofi ...
GlobalData on MSN4d
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
FierceBiotech5d
ASH: Sanofi's BTK inhibitor raises platelet levels in 23% of ITP patients in phase 3
Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...
labiotech6d
From consumer health to pure biopharma: Inside Sanofi’s strategic shift
In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with ...